These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 27145095)

  • 1. CRISPR/Cas9 genome editing in human pluripotent stem cells: Harnessing human genetics in a dish.
    González F
    Dev Dyn; 2016 Jul; 245(7):788-806. PubMed ID: 27145095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Scaled Framework for CRISPR Editing of Human Pluripotent Stem Cells to Study Psychiatric Disease.
    Hazelbaker DZ; Beccard A; Bara AM; Dabkowski N; Messana A; Mazzucato P; Lam D; Manning D; Eggan K; Barrett LE
    Stem Cell Reports; 2017 Oct; 9(4):1315-1327. PubMed ID: 29020615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Editing and Human Pluripotent Stem Cells: Tools for Advancing Diabetes Disease Modeling and Beta-Cell Development.
    Millette K; Georgia S
    Curr Diab Rep; 2017 Oct; 17(11):116. PubMed ID: 28980194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studying Kidney Disease Using Tissue and Genome Engineering in Human Pluripotent Stem Cells.
    Garreta E; González F; Montserrat N
    Nephron; 2018; 138(1):48-59. PubMed ID: 28988229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome Editing in Human Pluripotent Stem Cells.
    Carlson-Stevermer J; Saha K
    Methods Mol Biol; 2017; 1590():165-174. PubMed ID: 28353269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells.
    Lotfi M; Morshedi Rad D; Mashhadi SS; Ashouri A; Mojarrad M; Mozaffari-Jovin S; Farrokhi S; Hashemi M; Lotfi M; Ebrahimi Warkiani M; Abbaszadegan MR
    Stem Cell Rev Rep; 2023 Nov; 19(8):2576-2596. PubMed ID: 37723364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-automated optimized method to isolate CRISPR/Cas9 edited human pluripotent stem cell clones.
    Frank E; Cailleret M; Nelep C; Fragner P; Polentes J; Herardot E; El Kassar L; Giraud-Triboult K; Monville C; Ben M'Barek K
    Stem Cell Res Ther; 2023 Apr; 14(1):110. PubMed ID: 37106426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An episomal vector-based CRISPR/Cas9 system for highly efficient gene knockout in human pluripotent stem cells.
    Xie Y; Wang D; Lan F; Wei G; Ni T; Chai R; Liu D; Hu S; Li M; Li D; Wang H; Wang Y
    Sci Rep; 2017 May; 7(1):2320. PubMed ID: 28539611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.
    Ihry RJ; Worringer KA; Salick MR; Frias E; Ho D; Theriault K; Kommineni S; Chen J; Sondey M; Ye C; Randhawa R; Kulkarni T; Yang Z; McAllister G; Russ C; Reece-Hoyes J; Forrester W; Hoffman GR; Dolmetsch R; Kaykas A
    Nat Med; 2018 Jul; 24(7):939-946. PubMed ID: 29892062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pipeline for the Generation and Characterization of Transgenic Human Pluripotent Stem Cells Using the CRISPR/Cas9 Technology.
    Mianné J; Bourguignon C; Nguyen Van C; Fieldès M; Nasri A; Assou S; De Vos J
    Cells; 2020 May; 9(5):. PubMed ID: 32466123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient scarless genome editing in human pluripotent stem cells.
    Ikeda K; Uchida N; Nishimura T; White J; Martin RM; Nakauchi H; Sebastiano V; Weinberg KI; Porteus MH
    Nat Methods; 2018 Dec; 15(12):1045-1047. PubMed ID: 30504872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecules promote CRISPR-Cpf1-mediated genome editing in human pluripotent stem cells.
    Ma X; Chen X; Jin Y; Ge W; Wang W; Kong L; Ji J; Guo X; Huang J; Feng XH; Fu J; Zhu S
    Nat Commun; 2018 Apr; 9(1):1303. PubMed ID: 29610531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly Efficient CRISPR/Cas9-Mediated Genome Editing in Human Pluripotent Stem Cells.
    Maguire JA; Gadue P; French DL
    Curr Protoc; 2022 Nov; 2(11):e590. PubMed ID: 36426905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of genome-edited pluripotent stem cells and mice by CRISPR/Cas.
    Horii T; Hatada I
    Endocr J; 2016; 63(3):213-9. PubMed ID: 26743444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Gene Editing in Human Pluripotent Stem Cells Using Site-Specific Nucleases.
    Merkert S; Martin U
    Adv Biochem Eng Biotechnol; 2018; 163():169-186. PubMed ID: 29124278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precise and efficient scarless genome editing in stem cells using CORRECT.
    Kwart D; Paquet D; Teo S; Tessier-Lavigne M
    Nat Protoc; 2017 Feb; 12(2):329-354. PubMed ID: 28102837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-based Targeted Genome Editing for the Development of Monogenic Diseases Models with Human Pluripotent Stem Cells.
    Gupta N; Susa K; Yoda Y; Bonventre JV; Valerius MT; Morizane R
    Curr Protoc Stem Cell Biol; 2018 May; 45(1):e50. PubMed ID: 30040245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CRISPR/Cas system for genome editing in pluripotent stem cells].
    Vasil'eva EA; Melino D; Barlev NA
    Tsitologiia; 2015; 57(1):19-30. PubMed ID: 25872372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TALEN- and CRISPR/Cas9-Mediated Gene Editing in Human Pluripotent Stem Cells Using Lipid-Based Transfection.
    Hendriks WT; Jiang X; Daheron L; Cowan CA
    Curr Protoc Stem Cell Biol; 2015 Aug; 34():5B.3.1-5B.3.25. PubMed ID: 26237572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 Genome Engineering in Human Pluripotent Stem Cells for Modeling of Neurological Disorders.
    Canals I; Ahlenius H
    Methods Mol Biol; 2021; 2352():237-251. PubMed ID: 34324191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.